Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs

Submitted by amarin on Mon, 05/16/2022 - 12:01
Home
News
Research Presented at the American Heart Association’s Quality of Care and Outc…
DUBLIN, Ireland and BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and cost-effectiveness of VASCEPA® (icosapent ethyl), presented in two poster presentations at the American Heart

Amarin to Present at Two Upcoming Investor Conferences

Submitted by amarin on Thu, 05/12/2022 - 12:00
Home
News
Amarin to Present at Two Upcoming Investor Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, will present at two upcoming investor conferences: H.C. Wainwright Global Investment Conference  (May

Amarin Reports First Quarter 2022 Financial Results and Provides Business Update

Submitted by amarin on Wed, 05/04/2022 - 11:01
Home
News
Amarin Reports First Quarter 2022 Financial Results and Provides Business Update
  Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Continued Progress on Go-To-Market Strategy in the US Plans for Regulatory Filings for Approval

New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack)

Submitted by amarin on Tue, 05/03/2022 - 12:02
Home
News
New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardio…
The latest prespecified and post hoc sub-analysis of the landmark REDUCE-IT ® study, published today in the Journal of the American College of Cardiology (JACC), demonstrated that VASCEPA ® (icosapent ethyl) significantly reduces the total ischemic event risk of cardiovascular death, stroke,

Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)

Submitted by amarin on Tue, 04/26/2022 - 12:49
Home
News
Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-C…
DUBLIN, Ireland and BRIDGEWATER, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today its partner HLS Therapeutics has completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA) for the terms and conditions under which VASCEPA®

Mason RP, Eckel RH. Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction.

Submitted by amarin on Wed, 04/20/2022 - 15:19
Home
News
Mason RP, Eckel RH. Mechanistic insights from REDUCE-IT STRENGTHen the case aga…

Mason RP, Eckel RH. Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction. Am J Med. 2021; 134(9):1085-1090. 

Nelson JR, Budoff MJ, Wani OR, Le V, Patel DK, Nelson A, Nemiroff RL. EPA's pleiotropic mechanisms of action:

Submitted by amarin on Wed, 04/20/2022 - 15:14
Home
News
Nelson JR, Budoff MJ, Wani OR, Le V, Patel DK, Nelson A, Nemiroff RL. EPA's ple…

Nelson JR, Budoff MJ, Wani OR, Le V, Patel DK, Nelson A, Nemiroff RL. EPA's pleiotropic mechanisms of action: a narrative review. Postgrad Med. 2021;133:651-664. 

https://www.tandfonline.com/doi/full/10.1080/00325481.2021.1921491 

Subscribe to